title: Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity.
abstract: OBJECTIVE
  Several studies have shown arterial stiffness changes associated with coronary artery disease (CAD). Recently, statins were reported to improve arterial stiffness. The aim of the study was to evaluate the effect of atorvastatin on arterial stiffness in CAD patients using pulse wave velocity (PWV).
  
  
  METHODS
  We evaluated 63 patients with hyperlipemia and CAD. Forty-three patients were given 10mg atorvastatin daily and 20 patients were assigned to a low-fat diet. Carotid-femoral PWV (PWV-CF), carotid-radial PWV (PWV-CR) and carotid-distal PWV (PWV-CD) were measured in all patients.
  
  
  RESULTS
  Compared with baseline, PWV-CF, PWV-CR and PWV-CD decreased after therapy in the atorvastatin group (13.22+/-3.39 & 11.85+/-2.87; 11.85+/-2.72 & 10.73+/-2.31; and 11.04+/-1.99 & 10.15+/-1.75, P < 0.05). There was no difference in the control group (13.29+/-2.89 & 13.93+/-2.89; 11.52+/-2.25 & 12.31+/-2.22; and 10.46+/-1.86 & 11.15+/-1.85, P > 0.05). After treatment, values of total cholesterol, triglyceride and low density lipoprotein (LDL) cholesterol were reduced in the 2 groups (P < 0.05).
  
  
  CONCLUSIONS
  The study demonstrated that atorvastatin can improve arterial stiffness in CAD patients independent of its lipid-lowering properties.
authors.affiliation: Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Qilu Hospital, Shandong University, Jinan, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Meng
authors.forename: Liangyi
authors.initials: L
authors.lastname: Qie
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Wang
authors.forename: Ming
authors.initials: M
authors.lastname: Zhong
authors.forename: Li
authors.initials: L
authors.lastname: Li
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001158:Arteries / Q000187:drug effects* / Q000503:physiopathology; D000069059:Atorvastatin; D003187:Compliance; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin